The effect of glycopyrronium bromide on hypersalivation in patients with Parkinson's disease: a randomised, cross-over, double blind, placebo-controlled trial

INTERVENTION: Week one: baseline measurements Week two: glycopyrronium bromide (three times 1 mg [5 ml] daily) or placebo (three times 5 ml daily) will be taken Week three: new baseline measurements Week four: cross‐over glycopyrronium bromide (three times 1 mg [5 ml] daily) or placebo (three times 5 ml daily) will be taken Week five: final visit Patients score the extent of hypersalivation three times a day on a daily basis (scale from one to nine). CONDITION: Parkinsonian patients, hypersalivation ; Nervous System Diseases ; Extrapyramidal and movement disorders PRIMARY OUTCOME: Percentage of patients with a decrease of three points on the hypersalivation score (on a scale from one to nine). SECONDARY OUTCOME: The difference in mean improvement on the hypersalivation score between the two groups. Furthermore, the difference in reported adverse events will be analysed. INCLUSION CRITERIA: 1. Patients with Parkinson's disease 2. Aged more than or equal to 18 years 3. Hypersalivation score more than or equal to five (on a scale from one to nine) 4. Patient or family is able to score the extent of hypersalivation